Porous Embolic Composition for Controlled Partial Vessel Occlusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing embolization therapies lack embolic agents that provide controllable levels of stasis without complex injection and waiting protocols, particularly in procedures requiring partial or variable occlusion.
Innovation Solution
Embolic compositions containing a carrier liquid that solidifies to form a solid occlusion matrix, with dissipatable microparticles dispersed within, allowing the microparticles to be dissipated by blood flow, creating a porous structure for controlled occlusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If microparticles are used to enable controllable extent of stasis, then the extent of blood flow occlusion can be controlled, but complex injection and waiting protocols are required
Solution Approach 1:
The embolic composition is pre-formulated with dissolvable microparticles dispersed in a liquid carrier at optimal concentrations. The composition is ready-to-use with predetermined properties that enable controllable stasis without requiring complex injection protocols or waiting periods for assessment
Solution Approach 2:
The invention changes the physical state parameters of the embolic agent by using a liquid carrier that can be easily injected and then transitions to a solid occlusion matrix. The dissolvable microparticles provide gradual degradation, enabling controlled stasis adjustment without complex protocols
2Reliability
If complete occlusion is achieved to block blood flow downstream, then tumor necrosis and shrinkage occur, but total stasis may cause infarction of surrounding healthy tissue
Solution Approach 1:
The embolic composition provides dynamic control of blood flow occlusion. The liquid carrier allows initial flow modulation, while the dissolvable microparticles gradually degrade over time, transitioning from near-complete occlusion to partial occlusion. This dynamic behavior enables tumor necrosis while preserving blood flow to healthy surrounding tissue
Solution Approach 2:
The dissolvable microparticles create a porous structure within the solid occlusion matrix as they gradually dissolve. This porous structure allows controlled blood flow through the occlusion site, enabling sufficient occlusion for tumor treatment while maintaining perfusion to adjacent healthy tissue
3Adaptability or versatility
If microparticles are injected slowly to avoid over-embolization and particle reflux, then control over stasis extent is improved, but treatment time increases due to periodic waiting times
Solution Approach 1:
The embolic composition is pre-formulated with optimal microparticle concentration and size distribution dispersed in a liquid carrier. This preliminary preparation enables controlled stasis without requiring slow injection rates or periodic waiting times, significantly reducing overall treatment time
Solution Approach 2:
The liquid carrier enables continuous, smooth injection of the embolic composition without interruption. The dissolvable microparticles provide continuous gradual degradation after injection, eliminating the need for periodic waiting periods to assess stasis extent, thereby maintaining continuous useful action throughout the procedure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The embolic compositions enable controlled partial occlusion by forming a porous matrix, allowing blood flow while maintaining mechanical integrity, adaptable to various clinical scenarios through microparticle selection and distribution.
Implementation Method 1
a carrier liquid that solidifies to form a solid occlusion matrix at a target site in a blood vessel
Implementation Method 2
microparticles that are dissipated out of the solid occlusion matrix by action of blood flow in the blood vessel against the solid occlusion matrix
Data Source
AI summary
Embolic compositions include a carrier liquid that solidifies to form a solid occlusion matrix at a target site in a blood vessel, and a dissipatable solid additive contained within the carrier liquid. The dissipatable solid additive includes microparticles that are substantially insoluble in the carrier liquid, that are dispersed in the matrix upon solidification of the matrix, and that are dissipated out of the matrix by action of blood flow in the blood vessel against the matrix. Thereby, the matrix develops a porous structure and the blood vessel at the target site is less than totally occluded after dissipation of the additive. Methods of occluding a blood vessel include injecting the embolic composition to a target site in a blood vessel, allowing the embolic composition to solidify, and allowing the dissipatable solid additive to be dissipated from the solid occlusion matrix by blood flow in the blood vessel.